Leptomeningeal metastases: A RANO proposal for response criteria

Neuro-Oncology

Volumn 19, Issue 4, 2017, Pages 484-492

  Chamberlain, Marc ^a   Junck, Larry ^b   Brandsma, Dieta ^c   Soffietti, Riccardo ^d   Rudà, Roberta ^d   Raizer, Jeffrey ^e   Boogerd, Willem ^c   Taillibert, Sophie ^f   Groves, Morris D ^g   Le Rhun, Emilie ^h   Walker, Julie ⁱ   Van Den Bent, Martin ^j   Wen, Patrick Y ^k   Jaeckle, Kurt A ^l  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d Main Hospital and University   (Italy)

^e NORTHWESTERN UNIVERSITY   (United States)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g TEXAS ONCOLOGY   (United States)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l MAYO CLINIC   (United States)

more..

Author keywords

CSF cytology flow cytometry; Leptomeningeal metastasis; Neuraxis MRI; Neurological examination

Indexed keywords

CEREBROSPINAL FLUID CYTOLOGY; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; MENINGEAL METASTASIS; NERVE FIBER; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RADIODIAGNOSIS; REVIEW; TREATMENT OUTCOME; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; MENINGIOMA; STANDARDS;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 85019493398     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now183     Document Type: Review

References (61)

1. Chamberlain MC, Soffietti R, Raizer, et al. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 2014;16(9):1176-1185.
2. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987; 5(10):1655-1662.
3. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11(3):561-569.
4. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-3402.
5. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110-3116.
6. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40(18):2726-2733.
7. Shapiro WR, Schmid M, Glantz M, et al. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis [abstract]. J Clin Oncol. 2006; 24(June 6 suppl.):1528.
8. Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008;10(2):208-215.
9. Gajjar A, Fouladi M, Walter AW, et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol. 1999;17(6):1825-1828.
10. Armstrong TS, Wefel JS, Wang M, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31(32):4076-4084.
11. Brandberg Y, Johansson H, Aamdal S, et al. Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. Acta Oncol. 2013;52(6):1086-1093.
12. Chamberlain MC. Neoplastic meningitis: deciding who to treat. Expert Rev Neurotherap. 2004;4(4):89-96.
13. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161-166.
14. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neuro Oncol. 1998;38(2-3):151-157.
15. Jung H, Sinnarajah A, Enns B, et al. Managing brain metastases patients with and without radiotherapy: initial lessons from a team-based consult service through a multidisciplinary integrated palliative oncology clinic. Support Care Cancer. 2013;21(12):3379-3386.
16. Quinten C, Martinelli F, Coens C, et al. Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120(2):302-311.
17. Glass JP, Melamed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369-1375.
18. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733-739.
19. Chamberlain MC, Glantz M, Groves MD, et al. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 2009;36(suppl):S35-45.
20. Strik H, Luthe H, Nagel I, et al. Automated cerebrospinal fluid cytology: limitations and reasonable applications. Anal Quant Cytol Histol. 2005;27(3):167-173.
21. Rogers LR, Duchesneau PM, Nunez C, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology. 1992;42(6):1239-1241.
22. Nuckel H, Novotny J, Noppeney R, et al. Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry. Clin Lab Haem. 2006;28(1):22-29.
23. Aune MW, Becker JL, Brugnara C, et al. Automated flow cytometric analysis of blood cells in cerebrospinal fluid: analytic performance. Am J Clin Pathol. 2004;121(5):690-700.
24. Sancho JM, Orfao A, Quijano S, et al. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol. 2010;85(4):321-328.
25. Dux R, Kindler-Röhrborn A, Annas M, et al. A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid. J Neurol Sci. 1994;121(1):74-78
26. Hedge U, Fille A, Little RF, et al. High incidence of occult leptomenigeal disease detected by flow cytometry in newly diagnosed aggresive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-502.
27. Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007; 68(20):1674-1679.
28. Benevolo G, Stacchini A, Spina M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012; 120(16):3222-3228.
29. Nowakowski GS, Call TG, Morice WG, et al. Clinical significance of monoclonal B cells in cerebrospinal fluid. Cytometry B Clin Cytom. 2005;63(1):23-27.
30. de Graaf MT, de Jongste AH, Kraan J, et al. Flow cytometric characterization of cerebrospinal fluid cells. Cytometry B Clin Cytom. 2011;80(5):271-281.
31. Quijano S, Lopez A, Manuel SJ, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009; 27(9):1462-1469.
32. Kraan J, Gratama JW, Haioun C, et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom. 2008;Chapter 6: Unit6.25.
33. Nayak L, Fleisher M, Gonzalez-Espinosa R, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastaseis in slide tumors. Neurology. 2013;80(17):1598-1605.
34. Patel AS, Allen JE, Dicker DT, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752-760.
35. Le Rhun E, Massin F, Tu Q, et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12(1):21.
36. Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al. Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol. 2013;30(2):538.
37. Subira D, Simo M, Illan J, et al. Diagnostic and prognostic significance of flow cytometry immunophenophenotyping in patients with leptomeningeal carcinomatosis. Clin Exp Metastasis. 2015;32(4):383-391.
38. Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology. 1998;50(4):1173-1175.
39. Groves M, Hess KR, Puduvalli VK, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009;94(2):229-234.
40. Corsini E, Bernardi G, Gaviani P, et al. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med. 2009;47(7):874-879.
41. Römpp A, Dekker L, Taban I, et al. Identification of leptomeningeal metastasis-related proteins in cerebro-spinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. Proteomics. 2007;7(3):474-481.
42. Weston CL, Glantz MJ, Connor JR. Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. Fluids Barriers CNS. 2011;8(1):14.
43. Walbert T, Groves MD. Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Future Oncol. 2010;6(2):287-297.
44. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neuro Oncol. 1995;23(3):233-238.
45. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51-57.
46. Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997;54(11):1364-1368.
47. Clarke JL, Perez HR, Jacks LM, et al. Leptomeningeal metastasis in the MRI era. Neurology. 2010;74(8):1449-54.
48. Pauls S, Fischer AC, Brambs HJ, et al. Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors. Eur J Radiol. 2012;81(5):974-978.
49. Chamberlain MC. Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncology. 2013;2(2):121-128.
50. Smirniotopoulos JG, Murphy FM, Rushing EJ, et al. Patterns of contrast enhancement in the brain and meninges. Radiographics. 2007;27(2):525-551.
51. Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol. 2002;23(5):817-821.
52. Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumor brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes: a report from the RANO group. Lancet Oncol. 2013;14(10):e407-416.
53. Grossman SA, Trump CL, Chen DCP, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. Am J Med. 1982;73(5):641-647.
54. Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46(6):1674-1677.
55. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neuro Oncol. 1998;38(2-3):135-140.
56. Chamberlain MC, Kormanik P, Jaeckle KA, et al. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1999;52(1):216-217.
57. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1998;50(2):438-444.
58. Mittl RL, Jr, Yousem DM. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. Am J Neuroradiol. 1994;15(4):633-8.
59. Mathews VP, Caldemeyer KS, Lowe MJ, et al. Brain: gadolinium-enhanced fast fluid attenuated inversion recovery MR imaging. Radiology. 1999;211(1):257-263.
60. Mamourian AC, Hoopes PJ, Lewis LD. Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion recovery MR images: an in vitro and animal model investigation. AJNR Am J Neuroradiol. 2000;21(1):105-111.
61. Fukuoka H, Hirai T, Okuda T, et al. Comparison of the added value of contrast enhanced 3D fluid-attenuated inversion recovery and magnetization prepared rapid acquisition of gradient echosequences in relation to conventional postcontrast TW-weighted images for the evaluation of leptomeningeal diseases at 3T. AJNR Am J Neuroradiol. 2010;31(5):868-873.